We are happy to announce the Bing Center's presentation of 6 posters at the ASCO annual meeting, June 4-8, 2010 at the McCormick Place convention center, Chicago, IL. Here are the photos of the poster presentations.

Steven Treon, Zachary Hunter, Thea Ioakimidis, Chris Patterson, Jake Soumerai, Guang Yang

Guang Yang The CD20 directed monoclonal antibody GA101 demonstrates more robust activity relative to Rituximab in Waldenstrom’s Macroglobulinemia (WM), and may be particularly applicable to those patients expressing FcgRIIIA-158 F/F.

Jake Soumerai Phase II Study of Alemtuzumab in Lymphoplasmacytic Lymphoma (Waldenstrom’s Macroglobulinemia): Long Term Follow-Up of WMCTG trial 02-079.

Steven Treon Clinical characteristics and treatment outcome of disease related peripheral neuropathy in Waldenstrom’s Macroglobulinemia (WM).

Thea Ioakimidis Maintenance Rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom’s Macroglobulinemia (WM) who respond to a rituximab containing regimen.

Zachary Hunter The attainment of CR/VGPR is associated with significantly longer progression free survival in rituximab naïve WM patients undergoing rituximab based therapy, and is predicted by polymorphisms in FcgRIIIA-158.

Doug McMillin The NEDD8-specific inhibitor MLN 4924 exhibits activity in multiple myeloma and Waldenström’s Macroglobulinemia and modulates miRNA expression.